Showing 1 - 3 results of 3 for search 'Ting-Ting Xie', query time: 0.03s Refine Results
  1. 1
    Yu-Ping-Feng Formula Ameliorates Alveolar-Capillary Barrier Injury Induced by Exhausted-Exercise via Regulation of Cytoskeleton

    Yu-Ping-Feng Formula Ameliorates Alveolar-Capillary Barrier Injury Induced by Exhausted-Exercise via Regulation of Cytoskeleton by Di Wang, Di Wang, Di Wang, Di Wang, Di Wang, Quan Li, Quan Li, Quan Li, Quan Li, Chun-Shui Pan, Chun-Shui Pan, Chun-Shui Pan, Chun-Shui Pan, Li Yan, Li Yan, Li Yan, Li Yan, Kai Sun, Kai Sun, Kai Sun, Kai Sun, Xiao-Yi Wang, Xiao-Yi Wang, Xiao-Yi Wang, Xiao-Yi Wang, Xiao-Yi Wang, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Qian-Zan Liao, Qian-Zan Liao, Qian-Zan Liao, Qian-Zan Liao, Qian-Zan Liao, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Jing-Yu Fan, Jing-Yu Fan, Xin-Mei Huo, Xin-Mei Huo, Xin-Mei Huo, Xin-Mei Huo, Xin-Mei Huo, Yuan Wang, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway

    QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway by Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Gulinigaer Anwaier, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Ting-Ting Xie, Chun-Shui Pan, Chun-Shui Pan, Chun-Shui Pan, Chun-Shui Pan, Chun-Shui Pan, Chun-Shui Pan, An-Qing Li, An-Qing Li, An-Qing Li, An-Qing Li, An-Qing Li, An-Qing Li, An-Qing Li, Li Yan, Li Yan, Li Yan, Li Yan, Li Yan, Li Yan, Di Wang, Di Wang, Di Wang, Di Wang, Di Wang, Di Wang, Di Wang, Fan-Kai Chen, Fan-Kai Chen, Fan-Kai Chen, Fan-Kai Chen, Fan-Kai Chen, Fan-Kai Chen, Fan-Kai Chen, Ding-Zhou Weng, Ding-Zhou Weng, Ding-Zhou Weng, Ding-Zhou Weng, Ding-Zhou Weng, Ding-Zhou Weng, Ding-Zhou Weng, Kai Sun, Kai Sun, Kai Sun, Kai Sun, Kai Sun, Kai Sun, Xin Chang, Xin Chang, Xin Chang, Xin Chang, Xin Chang, Xin Chang, Xin Chang, Jing-Yu Fan, Jing-Yu Fan, Jing-Yu Fan, Jing-Yu Fan, Jing-Yu Fan, Jing-Yu Fan, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jing-Yan Han, Jian Liu, Jian Liu, Jian Liu, Jian Liu, Jian Liu, Jian Liu

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront

    Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront by Xiao Xiao Li, Wen Hui Huang, Xiao Bin Yang, Qi Lin Yang, Yu Zheng, Yong Bao Huo, Ting Ting Xie, Cheng Hui Huang, Shui Lian Yu

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: